Two Sigma Securities LLC Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Two Sigma Securities acquired 5,585 shares of Alnylam Pharmaceuticals in the second quarter, worth approximately $1.68 million. Hedge funds and institutional investors collectively own 92.97% of the company.
• Analysts maintain a generally positive outlook, with three Strong Buy, 16 Buy, and five Hold ratings. However, several firms recently cut their price targets, and the stock carries a consensus “Moderate Buy” rating with an average target of $386.14.
• Alnylam reported quarterly EPS of $1.84, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below expectations. Shares opened at $237.10, well below their 52-week high of $495.55.

Two Sigma Securities LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,585 shares of the biopharmaceutical company's stock, valued at approximately $1,681,000.

A number of other hedge funds also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Golden State Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ALNY shares. Truist Financial lowered their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Chardan Capital reissued a "buy" rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, July 31st. Finally, Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a "buy" rating on the stock in a report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $386.14.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $237.10 on Monday. The stock has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The firm has a 50 day moving average of $262.62 and a 200 day moving average of $293.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. Alnylam Pharmaceuticals's revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.51) EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source